Abstract: The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 ?m in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof.

Abstract: The present invention relates to the preparation of a solid catalytic composition based on a functionalized porous organic material, wherein: (A) organogelator compounds are self-assembled, within a medium comprising organic monomers, in the form of fibrillar structures having a diameter ranging from 10 nm to 100 nm; and then (B) the monomers are then polymerized; and then (C) the organogelator compounds are extracted from the polymer material, thereby obtaining a porous polymer material (M0), wherein the monomers bear reactive R functions, for which the presence is sought on the material; or said reactive R functions in protected form; or functions able to allow grafting of said reactive R functions on the polymer materials; and wherein, following step (C), (D) all or part of the functions present at the walls of the mesopores of the polymer material (M0) are converted where appropriate into reactive R functions and a composition is recovered comprising a porous polymer material (M) bearing the reactive R fu

Abstract: The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly suitable for the production of medicaments based on active ingredients which have low solubility or very low solubility in water or which are virtually insoluble in water.

Abstract: The present invention relates to a method for preparing an oral lyophilizate composition comprising: a) forming a liquid phase by using at least one homogenising agent having tensioactive properties, said liquid phase comprising at least an active pharmaceutical ingredient, a filler and/or a binding agent and a solvent, b) lyophilizing said liquid phase to form the oral lyophilizate composition.

Abstract: A safety starter circuit for a gas discharge lamp includes a series arrangement of a glow switch starter, a resistive element, and a thermally controlled switching element. The thermally controlled switching element is in a heat transfer relationship with the resistive element so that the thermally controlled switching element is effectively heated by heat generated in the resistive element. The thermally controlled switching element is designed to make a transition from a conductive state to a non-conductive state when its temperature exceeds a predetermined cut-off temperature. The thermally controlled switching element is arranged in a gas-tight casing.

Abstract: The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 ?m in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof.

Abstract: A safety starter circuit for a gas discharge lamp is described, comprising a series arrangement of: a glow switch starter (5); at least one resistive element (9); a thermally controlled switching element (8). The thermally controlled switching element (8) is in a heat transfer relationship with the resistive element (9) so that the thermally controlled switching element (8) is effectively heated by heat generated in the resistive element (9). The thermally controlled switching element (8) is designed to make a transition from a conductive state to a non-conductive state when its temperature exceeds a predetermined cut-off temperature. According to the invention, the thermally controlled switching element (8) is arranged in a gas-tight casing (7a).

Abstract: The present invention provides an orally dissolvable/disintegrable, lyophilized dosage form including a protected granulate comprising an active ingredient and a protective granulation binder, which substantially protects the form and/or attributes of a granulate and/or active ingredient, and participates in masking bad tasting active ingredients, such as sulfur-containing materials, and a matrix, and a method for making same. There is also provided a method of treating a patient using any orally dissolvable/disintegrable lyophilized dosage form comprising the steps of placing the dosage form in the mouth of a patient in need of treatment, allowing the dosage form to disintegrate/dissolve sufficiently to allow it, and in particular, the protected granulate, to be swallowed as a solution, suspension or slurry, and swallowing the at least partially disintegrated/dissolved dosage form.

Abstract: The present invention provides an orally dissolvable/disintegrable, lyophilized, dosage form adapted for direct oral dosing, including an active pharmaceutical ingredient (“API”) containing particle which is coated with a lyophilizing solvent protective coating, which protects the form and/or attributes of the particle and/or API, and a matrix. There is also provided a method of making an orally dissolvable/disintegrable lyophilized dosage form in accordance with the present invention, and a method of treating a patient with a dosage form in accordance with the present invention.

Abstract: The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 ?m in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof.

Abstract: The present invention relates to a process for the preparation of particles each comprising an excipient forming a matrix and at least one active ingredient uniformly distributed in the mass of said matrix, said process, which comprises the operations of extrusion and then lyophilization, being characterized in that it comprises the steps consisting of(1.) the preparation of a homogeneous mixture from(a) at least one active ingredient,(b) a physiologically acceptable hydrophilic excipient, and(c) waterto give a pasty mixture with a viscosity below 1 Pa.s, measured at room temperature (15.degree.-20.degree. C.);(2.) the extrusion of the resulting homogeneous mixture and the cutting of the extrudate to give moist particles;(3.) the freezing of the resulting particles as they fall under gravity through a stream of inert gas at a temperature below 0.degree. C.; and(4.) the freeze drying of said particles.